Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
RAGE shRNA
- Development stage
- Unknown
- Lead developer
- Santa Cruz Biotechnology
- Modality
- Viral-delivered RNAi → In Vivo RNAi → Gene Silencing → Gene Therapies, RNA Therapeutics → Nucleic Acid Therapeutics
- Administration
- Intratumoral
01
Overview
RAGE shRNA is a research-grade gene-silencing reagent designed to knock down the expression of the Receptor for Advanced Glycation Endproducts (RAGE), also known as AGER. It typically consists of a pool of lentiviral vector plasmids or constructs encoding target-specific 19–25 nucleotide short hairpin RNA (shRNA) sequences. By utilizing the RNA interference (RNAi) pathway, RAGE shRNA facilitates the degradation of RAGE mRNA, thereby reducing protein levels. This tool is primarily used in academic and preclinical research to investigate the role of RAGE signaling in various pathological conditions, including cancer progression (e.g., pancreatic and breast cancer), inflammation, diabetes, and Alzheimer's disease. It is not a therapeutic drug and is intended for research use only.
- Other names
- AGER shRNAReceptor for Advanced Glycation Endproducts short hairpin RNA
02
Targets
Advanced glycosylation end product-specific receptor (AGER) mRNA
Beyond the preview
Go deeper on RAGE shRNA.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on RAGE shRNA.